Spectrum News: UC researches racial health disparities in dementia
Hyacinth I. Hyacinth, PhD, MBBS, is currently leading a study seeking to determine how biological differences among racial groups contribute to higher rates of Alzheimer’s disease and related dementias among non-Hispanic Black compared with non-Hispanic white patients. Dementia is more than twice as prevalent in non-Hispanic Black populations compared to non-Hispanic white populations in the United States, after controlling for known risk factors.
Hyacinth, associate professor of neurology and rehabilitation medicine and the Whitaker and Price Chair in Brain Health in UC’s College of Medicine, told Spectrum News the research in part will examine whether there is a higher disease burden of cerebral small vessel disease (CSVD) in non-Hispanic Black patients compared to non-Hispanic white patients. A higher CSVD burden could be one reason for higher rates of dementia and cognitive impairment in non-Hispanic Black patients, he said.
“If we can demonstrate that there is some biology behind these racial disparities and cognitive impairment and dementia, then that becomes a potential target for therapy,” Hyacinth told Spectrum News.
Watch the Spectrum News story.
Featured photo of Hyacinth I. Hyacinth. Photo/Andrew Higley/University of Cincinnati.
Related Stories
Cincinnati Children's LEND Program opens doors for UC graduate nursing students
June 9, 2026
UC graduate nursing students are broadening their expertise and career opportunities through the Cincinnati Children's LEND Program.
Patients with developmental disabilities may benefit with an integrated care model
June 9, 2026
Researchers from the University of Cincinnati and Ohio State University have found that adults with developmental disabilities who have integrated care were less likely to go to the emergency room or be hospitalized than others who were not. Their work was published in Disability and Health Journal.
UC physician-researcher's work yields landmark five-year data for Crohn's disease drug
June 8, 2026
The University of Cincinnati College of Medicine’s Anita Afzali, MD, leads a landmark study revealing five-year efficacy and safety data for a Crohn’s disease drug called guselkumab.